A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

NCT ID: NCT02024607

Last Updated: 2023-11-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 495 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2019-11-30

Brief Summary

This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan.

Detailed Description

This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan. A study cycle will consist of daily and continuous oral administration of BBI608 for four weeks (28 days) in combination with FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan.

Conditions

Advanced Gastrointestinal Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ARM A- BBI608 in combination with FOLFOX6

BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously. 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2 over 46-48 hours) continuous intravenous infusion. This regimen will be repeated every 14 days thereafter.

Group Type: EXPERIMENTAL

BBI608

Intervention Type: DRUG

Fluorouracil

Intervention Type: DRUG

Oxaliplatin

Intervention Type: DRUG

Leucovorin

Intervention Type: DRUG

ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab

BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously. 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.

Group Type: EXPERIMENTAL

BBI608

Intervention Type: DRUG

Fluorouracil

Intervention Type: DRUG

Oxaliplatin

Intervention Type: DRUG

Leucovorin

Intervention Type: DRUG

Bevacizumab

Intervention Type: DRUG

ARM C- BBI608 in combination with CAPOX

BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m\^2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter. If capecitabine is tolerated at the 850 mg/m\^2 twice daily dose, dosage may be increased to 1000 mg/m\^2 twice daily as tolerated after the first cycle.

Group Type: EXPERIMENTAL

BBI608

Intervention Type: DRUG

Oxaliplatin

Intervention Type: DRUG

Capecitabine

Intervention Type: DRUG

ARM D- BBI608 in combination with FOLFIRI

BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously. 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion. This regimen will be repeated every 14 days thereafter.

Group Type: EXPERIMENTAL

BBI608

Intervention Type: DRUG

Fluorouracil

Intervention Type: DRUG

Leucovorin

Intervention Type: DRUG

Irinotecan

Intervention Type: DRUG

ARM E- BBI608 in combination with FOLFIRI and Bevacizumab

BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.

Group Type: EXPERIMENTAL

BBI608

Intervention Type: DRUG

Fluorouracil

Intervention Type: DRUG

Leucovorin

Intervention Type: DRUG

Irinotecan

Intervention Type: DRUG

Bevacizumab

Intervention Type: DRUG

ARM F- BBI608 in combination with Regorafenib

BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle.

Group Type: EXPERIMENTAL

BBI608

Intervention Type: DRUG

Regorafenib

Intervention Type: DRUG

Arm G- BBI608 in combination with Irinotecan

BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m\^2 will be administered intravenously. This regimen will be repeated every 14 days thereafter.

Group Type: EXPERIMENTAL

BBI608

Intervention Type: DRUG

Irinotecan

Intervention Type: DRUG

Interventions

BBI608

Intervention Type: DRUG

Fluorouracil

Intervention Type: DRUG

Oxaliplatin

Intervention Type: DRUG

Leucovorin

Intervention Type: DRUG

Irinotecan

Intervention Type: DRUG

Bevacizumab

Intervention Type: DRUG

Capecitabine

Intervention Type: DRUG

Regorafenib

Intervention Type: DRUG

Other Intervention Names

Napabucasin; BB608; BBI-608; 5-FU; Carac; Efudex; Fluoroplex; Adrucil; Eloxatin; Folinic Acid; Camptosar; Avastin; Xeloda; Stivarga

Eligibility Criteria

Inclusion Criteria

1. Signed written informed consent

2. A histologically confirmed solid tumor of the gastrointestinal tract including

1. Advanced unresectable, metastatic or recurrent colorectal carcinoma (CRC) for which treatment with FOLFOX6 with or without bevacizumab, FOLFIRI with or without bevacizumab, CAPOX, or regorafenib would be acceptable as determined by the Investigator. FOLFIRI/XELIRI-refractory patients with CRC enrolling on the FOLFIRI study arm must have failed treatment with one FOLFIRI pr XELIRI with or without bevacizumab regimen for unresectable or metastatic disease. Treatment failure is defined as progression of disease (clinical or radiologic) during treatment with FOLFIRI with or without bevacizumab or < 3 months after the last dose of treatment with FOLFIRI with or without bevacizumab. Patients with CRC enrolling on the regorafenib arm of this study will have previously received at least two previous lines of therapy for advanced colorectal cancer, and will have previously received treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients with K-ras wild type tumors enrolling on the regorafenib arm will also have previously received either cetuximab or panitumumab.

2. Hepatocellular carcinoma for which treatment with FOLFOX6 or CAPOX would be acceptable as determined by the Investigator.

3. Pancreatic adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the Investigator.

4. Cholangiocarcinoma for which treatment with FOLFOX6 or CAPOX would be acceptable as determined by the Investigator.

5. Gastric, GEJ or esophageal adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the Investigator.

3. Patients may be treatment naïve, or may have received standard chemotherapy; including regimens containing a fluoropyrimidine, or oxaliplatin, or irinotecan, or regorafenib, or bevacizumab.

4. ≥18 years of age.

5. Karnofsky performance status score ≥70%.

6. Male or female patients of child-producing potential agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI608 dose.

7. Females of childbearing potential have a negative serum pregnancy test.

8. AST level ≤2.5 x ULN and ALT ≤ 2.5 × ULN. For patients with liver metastases, AST ≤3.5 x ULN, and AST ≤3.5 x ULN may be enrolled if agreed upon by the investigator and medical monitor for the sponsor.

9. Hemoglobin ≥10 g/dl.

10. Total bilirubin level ≤1.5 × ULN.

11. Creatinine ≤1.5 x ULN or creatinine clearance >60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal (as determined by Cockcroft-Gault equation).

12. Absolute neutrophil count ≥ 1.5 x 10^9/L.

13. Platelets ≥100 x 10^9/L.

14. Life expectancy estimated at ≥3 months.

Exclusion Criteria

1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 7 days of the first dose of BBI608.

2. Major surgery within 4 weeks prior to first dose.

3. Any known untreated brain metastases. Treated subjects must be stable for 4 weeks after completion of that treatment, with image documentation required. Patients must have no clinical symptoms from brain metastases and must be either off steroids or on a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients with known leptomeningeal metastases are excluded, even if treated.

4. Pregnant or breastfeeding.

5. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent

6. Unable or unwilling to swallow BBI608 capsules daily.

7. Prior treatment with BBI608.

8. Uncontrolled intercurrent illness

9. For patients to be treated with a regimen containing 5-fluorouracil/leucovorin:

1. Known hypersensitivity to 5-fluorouracil/leucovorin

2. Known dihydropyrimidine dehydrogenase (DPD) deficiency

10. For patients to be treated with a regimen containing capecitabine:

1. Known hypersensitivity to capecitabine

2. Known dihydropyrimidine dehydrogenase (DPD) deficiency

3. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent

11. For patients to be treated with a regimen containing oxaliplatin:

1. Neurosensory neuropathy ≥ grade 2 at baseline

2. Known hypersensitivity to oxaliplatin or other platinum containing compounds

12. For patients to be treated with a regimen containing irinotecan:

1. Known hypersensitivity to irinotecan

2. Abnormal glucuronidation of bilirubin

13. For patients to be treated with a regimen containing bevacizumab:

1. Current uncontrolled hypertension as well as prior history of hypertensive crisis or hypertensive encephalopathy

2. History of cardiac disease: congestive heart failure (CHF) > NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy

3. History of arterial thrombotic or embolic events (within 6 months prior to study entry)

4. Significant vascular disease

5. Evidence of bleeding diathesis or clinically significant coagulopathy

6. Major surgical procedure within 28 days, or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure within 7 days prior to study enrollment

7. Proteinuria at screening as demonstrated by urinalysis with proteinuria ≥ 2+.

8. History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or intra-abdominal abscess within 6 months

9. Ongoing serious, non-healing wound, ulcer, or bone fracture

10. Known hypersensitivity to any component of bevacizumab

11. History of reversible posterior leukoencephalopathy syndrome (RPLS)

14. For patients to be treated with a regimen containing regorafenib:

1. History of cardiac disease: congestive heart failure (CHF) > NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy

2. Current uncontrolled hypertension

3. Interstitial lung disease with ongoing signs and symptoms at the time of screening

4. History of HIV infection or chronic hepatitis B or C

5. Active clinically serious infections

6. History of arterial or embolic events (within 6 months prior to study entry)

7. Liver cirrhosis ≥ Child-Pugh class B with uncontrolled ascites

8. History of RPLS

9. Ongoing serious, non-healing wound, ulcer, or bone fracture

10. Evidence of bleeding diathesis or a clinically significant coagulopathy

11. Renal failure requiring hemo- or peritoneal dialysis

12. Persistent proteinuria of CTCAE grade 3 (>3.5g/24 hours)

13. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent

14. Known hypersensitivity to regorafenib

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sumitomo Pharma America, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Boston Biomedical

Role: STUDY_DIRECTOR

Sumitomo Pharma America, Inc.

Locations

Mayo Clinic Campus in Arizona

Phoenix, Arizona, United States

Florida Cancer Specialists

Fort Myers, Florida, United States

Emory University Winship Cancer Institute

Atlanta, Georgia, United States

Parkview Research Center

Fort Wayne, Indiana, United States

Indiana University Health Goshen Center for Cancer Care

Goshen, Indiana, United States

Indiana University Simon Cancer Center

Indianapolis, Indiana, United States

Indiana University Health Arnett Hospital

Lafayette, Indiana, United States

Indiana University Health Ball Memorial Hospital

Muncie, Indiana, United States

Mayo Clinic

Rochester, Minnesota, United States

Oncology Hematology Care, Inc.

Cincinnati, Ohio, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Institute for Translational Oncology Research, Greenville Health System

Greenville, South Carolina, United States

Tennessee Oncology - Chattanooga

Chattanooga, Tennessee, United States

Tennessee Oncology - Nashville

Nashville, Tennessee, United States

Ottawa Hospital Cancer Center

Ottawa, Ontario, Canada

Countries

United States; Canada

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

BBI608-246

Identifier Type: -

Identifier Source: org_study_id